CION Ameerpet
If you have been told there will be no biopsy before surgery, that is not a shortcut and not an oversight. Puncturing a contained ovarian tumour can spread it, and that single fact reshapes the whole diagnostic pathway.
Ovarian cancer is staged partly by whether it has escaped the ovary. A tumour still contained within an intact capsule is early-stage disease with a substantially better outlook. Once malignant cells are in the peritoneal cavity, the stage rises and treatment changes accordingly.
A needle passed through that capsule to take a sample creates exactly the breach the staging system is measuring. Cells can track along the needle path or spill into the abdominal cavity, and a cancer that was contained becomes one that is not. The test would change the thing it was measuring, and in the wrong direction.
The same logic applies during surgery, which is why surgeons take considerable care to remove an ovarian mass intact rather than allowing it to rupture. Where a cyst does rupture during an operation, that is documented, because it affects the stage. This is not surgical fussiness — it is the same principle that governs the decision not to biopsy beforehand.
A tumour inside an intact capsule is early-stage. Breaching it is precisely what raises the stage.
A needle through the capsule can spill cells and convert contained disease into disseminated disease.
Surgeons remove ovarian masses intact for the same reason, and document any rupture because it affects staging.
This is one of the clearest cases in medicine where the standard diagnostic sequence is deliberately reversed. For nearly every other solid tumour, the order is biopsy, then diagnosis, then treatment planned around it. For an operable ovarian mass the order becomes imaging, risk assessment, then surgery that diagnoses and treats simultaneously. Women frequently find this unsettling — being told they will have major surgery without a confirmed cancer diagnosis feels wrong, and nobody explains why. It is not a shortcut. It is a deliberate departure made because the usual first step carries a specific and avoidable harm. Source: NCCN Ovarian Cancer guidelines.
The principle is narrower than it first sounds. It applies to operable, apparently contained disease — not to everything.
Where imaging suggests disease that is confined and surgically removable. Here the tumour capsule is doing important work, and breaching it risks converting early-stage disease into advanced disease. The mass is removed intact at surgery, systematic staging samples are taken, and pathology on the whole specimen gives the definitive diagnosis. A frozen section during the operation guides how extensive the surgery should be. This is the standard pathway for apparently early ovarian cancer.
Where disease is already extensive and could not be removed completely at an initial operation — chemotherapy is given first, and that needs a tissue diagnosis, so the concern about spreading a contained tumour no longer applies. Also where the diagnosis is genuinely uncertain, since tuberculosis, lymphoma and cancers spreading from elsewhere all mimic ovarian cancer and need entirely different treatment. And where a woman is not fit for major surgery.
Avoiding a percutaneous biopsy of the ovarian mass does not mean going without a diagnosis. Several routes exist.
Where there is significant free fluid, a needle sample of it can provide malignant cells for examination without touching any contained ovarian mass at all. It is a short outpatient procedure under local anaesthetic, guided by ultrasound.
It is often the least invasive way to establish a diagnosis, and it does a second job at the same time — draining a larger volume relieves the pressure, early satiety and breathlessness that ascites causes. See ascites.
Where disease has already spread, there are usually accessible deposits outside the ovary — on the omentum, the peritoneum or elsewhere. Sampling one of those under image guidance gives a tissue diagnosis without disturbing the primary mass.
This is the standard approach where neoadjuvant chemotherapy is planned. Because the disease is already disseminated, the concern that governs the no-biopsy principle simply does not apply, and a proper tissue diagnosis is needed before chemotherapy can start.
Keyhole surgery that lets the surgeon see the abdominal cavity directly, assess how extensive disease is and whether complete removal is achievable, and take targeted biopsies under direct vision rather than blindly through the skin.
It is particularly useful where imaging is equivocal about whether upfront surgery would succeed. It avoids committing to a major operation that might not achieve its goal, while still providing proper tissue for diagnosis — a middle path that is often overlooked.
Where the operation goes ahead, a pathologist examines tissue while surgery is still under way and gives a preliminary answer within minutes. This guides how extensive the operation should be — whether to proceed to full staging and debulking, or to stop if the finding is benign.
It is preliminary rather than final. Definitive diagnosis comes from full histopathological examination over one to two weeks, and occasionally the final result differs. See reading a pathology report.
Some women with advanced ovarian cancer have fluid around the lung as well as in the abdomen. Sampling that is straightforward, and finding malignant cells in pleural fluid both establishes the diagnosis and confirms the stage.
It also relieves breathlessness where the volume is significant. As with ascites, this is a route to diagnosis that does not involve going near the ovarian mass itself.
Occasionally the imaging picture is characteristic enough, and the clinical situation clear enough, that a plan is made without any tissue at all — proceeding straight to surgery, with frozen section during the operation as the confirmatory step.
This is only appropriate where the pre-operative assessment is coherent: imaging, markers and risk score all pointing the same way, and reviewed at a tumour board rather than by one clinician. If your plan is this, it is entirely reasonable to ask whether it has been through a multidisciplinary discussion.
All reasonable, and asking them tends to improve the answers you get.
There should be a specific reason based on your imaging. A good team will explain it readily rather than treating it as odd to ask.
A multidisciplinary discussion before a plan is set is standard for suspected ovarian cancer, not an optional extra.
This depends on whether complete removal looks achievable. Ask what the imaging suggested and why.
Outcomes are better with a specialist gynaecologic-oncology surgeon. It is fair to ask directly.
Washings, peritoneal biopsies, omentum and nodes — even where things look normal. Incomplete staging may need repeating.
Tuberculosis and lymphoma mimic ovarian cancer. Ask whether alternatives have been considered.
If nobody has explained why there is no biopsy, that is a communication gap rather than a sign something is wrong. Ask — the reasoning is sound and easy to explain.
It is entirely reasonable to ask why, and a good team will explain it readily. If nobody has, that is a gap in communication rather than a sign something is wrong.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Bring your imaging reports — the plan usually follows directly from what they show.
This is the aspect women find hardest, and it deserves naming directly. Being told you need major abdominal surgery, without anyone having confirmed you have cancer, feels backwards. In every other context, a diagnosis comes first and treatment follows from it.
What helps is understanding that the pre-operative assessment is not guesswork. Ultrasound characterisation in trained hands classifies the large majority of ovarian masses confidently. Tumour markers, interpreted alongside imaging and menopausal status, add weight. A risk score combines them. Cross-sectional imaging maps the extent. By the time surgery is proposed, there is usually a well-founded assessment — it simply is not a tissue diagnosis.
And the operation itself resolves it, often within minutes. A frozen section during surgery gives a preliminary answer while you are still in theatre, and that answer guides how much surgery is done. Where the finding is benign, the operation stops there. It is genuinely possible to go into theatre uncertain and come out with both an answer and the treatment already completed.
Imaging, markers, risk scoring and cross-sectional imaging build a well-founded assessment before any operation.
A preliminary diagnosis within minutes, guiding how extensive the surgery should be.
Where frozen section shows benign disease, the surgery ends there rather than proceeding to full staging.
A good team explains why surgery is proposed and what the imaging showed. It is a fair question.
A great deal of the distress in this period comes from a plan that has been decided but not explained. Women are told there will be surgery, no biopsy, and a date — and left to work out for themselves why the usual order has been abandoned. The reasoning is sound and takes two minutes to explain, which makes the gap all the more frustrating.
Your first consultation at CION is free and runs to about 45 minutes. Bring your imaging reports. Much of the useful work is explaining what the scans actually showed, why the plan follows from that, and what the alternatives would be — including whether a diagnostic laparoscopy or an ascitic tap might give an answer with less commitment.
We should be clear about who does what. Debulking and staging surgery is coordinated with specialist gynaecologic-oncology partner centres and may be billed there — outcomes are better where this is done by a specialist surgeon, which is why it is arranged that way. Chemotherapy and maintenance therapy are delivered in-house at CION across 35+ centres, as are genetic counselling and BRCA and HRD testing. Every case that raises a question goes to a tumour board.
Free and unhurried. Long enough to explain why the usual diagnostic order has been reversed in your case.
Multidisciplinary review before a plan is set, rather than a decision by one clinician.
Staging and debulking performed at specialist gynaecologic-oncology partner centres and may be billed there.
Delivered across 35+ centres, so treatment continues near where you live.
Because puncturing a contained ovarian tumour risks spreading it. Ovarian cancer is staged partly by whether disease has escaped the ovary — a tumour still inside an intact capsule is early-stage with a substantially better outlook. A needle passed through that capsule can allow cells to track along the needle path or spill into the abdominal cavity, converting contained disease into disseminated disease. The test would change the thing it was measuring, in the wrong direction. So where disease appears operable, the mass is removed intact at surgery and pathology on the whole specimen gives the diagnosis.
Yes, and the pre-operative assessment is considerably more robust than the absence of a biopsy makes it sound. Ultrasound characterisation in trained hands classifies the large majority of ovarian masses confidently. Tumour markers interpreted alongside imaging and menopausal status add weight, a risk score combines them, and cross-sectional imaging maps the extent of disease. By the time surgery is proposed there is a well-founded assessment. During the operation a frozen section gives a preliminary pathological answer within minutes, guiding how extensive the surgery should be — and where the finding is benign, the operation stops there.
In several clear situations. Where imaging shows disease too extensive to remove completely at an initial operation, chemotherapy is given first — and that requires a tissue diagnosis, so the concern about breaching a contained tumour no longer applies since the disease is already disseminated. A biopsy is also appropriate where the diagnosis is genuinely uncertain, since abdominal tuberculosis, lymphoma and cancers spreading from the stomach or bowel can all mimic ovarian cancer and need entirely different treatment. And where a woman is not fit for major surgery, a diagnosis must be obtained another way.
Several alternatives exist that avoid disturbing a contained ovarian mass. Where there is free fluid in the abdomen, sampling it can provide malignant cells for examination — and draining a larger volume relieves symptoms at the same time. Where disease has spread, biopsying an accessible deposit on the omentum or peritoneum under image guidance gives a tissue diagnosis without touching the primary. Diagnostic laparoscopy allows targeted biopsies under direct vision while also assessing whether complete surgical removal is achievable. Pleural fluid can be sampled where there is a chest effusion.
A rapid pathological examination performed while the operation is still under way. A tissue sample is frozen, sectioned and examined immediately, giving the surgeon a preliminary answer within minutes rather than days. That guides how extensive the surgery should be — whether to proceed to full staging and debulking, or to stop if the finding is benign. It is preliminary rather than definitive: the final diagnosis comes from full histopathological examination over the following one to two weeks, and occasionally the final result differs from the frozen section.
What is worth asking is why the plan is what it is, rather than pressing for a specific test. There should be a clear reason based on your imaging, and a good team will explain it readily. Also worth asking: whether your case has been discussed at a tumour board, whether upfront surgery or chemotherapy first is planned and why, who will perform the surgery, and whether alternatives to ovarian cancer such as tuberculosis or lymphoma have been considered. If nobody has explained the absence of a biopsy, that is a communication gap rather than a sign anything is wrong.
The first consultation is free and runs to about 45 minutes — bring your imaging reports, since the plan usually follows directly from what they show. Debulking and staging surgery is coordinated with specialist gynaecologic-oncology partner centres and may be billed there; outcomes are better where this is performed by a specialist surgeon, which is why it is arranged that way. Chemotherapy and maintenance therapy including PARP-inhibitor-class treatment are delivered in-house at CION across more than 35 centres, as are genetic counselling and BRCA and HRD testing.